GlucoTrack appoints Erin Carter as director and Audit Committee Chair

Glucotrack, Inc.

Erin Carter appointed director and Audit Committee Chair effective August 25, 2023.
Carter brings 30 years of med device finance experience; was CFO of Medtronic's $9B Neuroscience division.
She replaces Shimon Rapps, who remains as a member of the Audit Committee.
Carter previously held senior finance roles at Boston Scientific, UnitedHealth Group, and Arterial Vascular Engineering.
Board cites her executive finance experience and life science leadership as qualifications.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erin Carter

Director and Audit Committee Chair

GCTK · Glucotrack, Inc.

Effective: 2023-08-25
Filed: August 31, 2023, 7:59 PM ET

On August 25, 2023, the Board of Directors of GlucoTrack, Inc. appointed Erin Carter as a director to serve until her successor is elected and duly qualifies.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erin Carter was appointed as Director and Audit Committee Chair at Glucotrack, Inc..

Action: appointed
Role: Director and Audit Committee Chair

Exact text from the filing

On August 25, 2023, the Board of Directors of GlucoTrack, Inc. appointed Erin Carter as a director to serve until her successor is elected and duly qualifies.

View on SEC.gov

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-031074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.